Site search

Clear filter
2927 results for '' found
A Phase 1 Study Investigating the Safety, Tumor Uptake, Biodistribution, and Dosimetry of [68Ga]Ga-A9-6217 in Participants with Select Advanced or Metastatic Solid Tumors (ACTRN12625000268448)
A Phase 1 Study Investigating the Safety, Tumor Uptake, Biodistribution, and Dosimetry of [68Ga]Ga-A9-6217 in Participants with Select Advanced or Metastatic Solid Tumors (ACTRN12625000268448)
/
A Phase I/II, first-in-human, open-label, dose escalation and indication expansion study of the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of BNT3212 as monot
A Phase I/II, first-in-human, open-label, dose escalation and indication expansion study of the safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy of BNT3212 as monot
/
A Phase 1a/b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C0902, an Antibody-Drug Conjugate Targeting EGFR MET, Alo
A Phase 1a/b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C0902, an Antibody-Drug Conjugate Targeting EGFR MET, Alo
/
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure Wi
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure Wi
/
A Phase 1a/b Open-Label Master Study of PF-07799544 as a Single-Agent and in Combination with Other Targeted Agents in Participants with BRAF-Mutant Melanoma and Other Solid Tumors (NCT05538130)
A Phase 1a/b Open-Label Master Study of PF-07799544 as a Single-Agent and in Combination with Other Targeted Agents in Participants with BRAF-Mutant Melanoma and Other Solid Tumors (NCT05538130)
/
CLEOPATTRA: Effects of NNC6019-0001 versus placebo on cardiovascular outcomes in participants with transthyretin amyloid cardiomyopathy [ATTR-CM] (NCT07207811)
CLEOPATTRA: Effects of NNC6019-0001 versus placebo on cardiovascular outcomes in participants with transthyretin amyloid cardiomyopathy [ATTR-CM] (NCT07207811)
/
First In Human Feasibility Clinical Study Evaluating the Safety of the XPD System for Periosteal Distraction [PD] (ACTRN12625000159459)
First In Human Feasibility Clinical Study Evaluating the Safety of the XPD System for Periosteal Distraction [PD] (ACTRN12625000159459)
/
First In Human Study to Assess Safety and Efficacy of the ChampioNIR Drug Eluting Peripheral Stent in the Treatment of Patients with Superficial Femoral Artery Disease and/or Proximal Popliteal A
First In Human Study to Assess Safety and Efficacy of the ChampioNIR Drug Eluting Peripheral Stent in the Treatment of Patients with Superficial Femoral Artery Disease and/or Proximal Popliteal A
/
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis [IPF] (NCT06967805)
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis [IPF] (NCT06967805)
/
An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physicians Choice in Hormone Receptorpositive, HER2-negative Unresectable Locally Advanc
An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physicians Choice in Hormone Receptorpositive, HER2-negative Unresectable Locally Advanc
/
1 2 3 4 5